Source: INOVIQ
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • INOVIQ (IIQ) signs a contract services agreement with US-based contract diagnostics organisation ResearchDx to further develop and validate the company’s SubB2M-based tests in the US
  • SubB2M-based tests are being developed for the monitoring and detection of cancer and its technology is based on an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc found in multiple human cancers
  • Under the agreement, ResearchDx will provide contract services including technology transfer, feasibility testing and assay development of the SubB2M-based tests, followed by analytical and clinical validation of the tests
  • IIQ shares last traded at 86 cents on April 4

INOVIQ (IIQ) has entered into a contract services agreement with US-based contract diagnostics organisation ResearchDx to further develop and validate the company’s SubB2M-based tests in the US.

SubB2M-based tests are being developed for the monitoring and detection of cancer and its technology is based on an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc found in multiple human cancers.

Under the agreement, ResearchDx will provide contract services including technology transfer, feasibility testing and assay development of the SubB2M-based tests, followed by analytical and clinical validation of the tests.

ResearchDx will initially undertake technology transfer, feasibility testing and assay development of the SubB2M-based tests incorporating the SubB2M/CA15.3 test for monitoring breast cancer, the SubB2M/CA125 test for monitoring ovarian cancer and the SubB2M-SPR test for detection of Neu5Gc concentrations.

INOVIQ will pay the agreed costs for the ResearchDx work and related sample, reagent and consumable expenditures.

“As a specialist contract diagnostic organisation with a US-based CAP/CLIA-certified laboratory, ResearchDx is an ideal partner to help progress the development and
commercialisation of our SubB2M-based tests in the US,” INOVIQ CEO Dr Leearne Hinch said.

“This agreement is important as it delivers two milestones in one with ResearchDx providing accredited CRO services and being a potential clinical laboratory partner for SubB2M-based lab developed tests in the US.”

IIQ shares last traded at 86 cents on April 4.

iiq by the numbers
More From The Market Online

Vulcan Energy Resources commences civil construction works at LEP site in Germany

Vulcan Energy Resources has commenced civil construction works for its commercial lithium extraction plant (LEP), part…

Southern Cross Electrical Engineering lands over $300m in data centre and buildings awards

Southern Cross Electrical Engineering subsidiaries have been awarded a range of projects totalling over $300 million.

TruScreen continues global growth with product registration in Kenya

TruScreen Group has received product registration in the Republic of Kenya, a priority market for cervical…
The Market Online Video

Market Open: A cautious start as Wall Street tech stocks retreat

Australian shares are expected to open relatively flat on Monday after another mixed session on Wall Street, where renewed selling in technology stocks